Suraksha Diagnostic Limited — Investor Meet, 05-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Suraksha Diagnostic reported FY25 income up 15% YoY to Rs. 256 Cr, EBITDA rising 16% to Rs. 85 Cr with stable ~34% margins, and PAT growing 34% to Rs. 31 Cr (margin 12.3%). Patient volume hit 1.19 million with 6.7 million tests. Network expanded 7 centers in FY25 and 8 in Q1 FY26, targeting 15-18 new centers this year backed by Rs. 70 Cr CAPEX. Acquisition of Fetomat Wellness (63%) broadens fetal/maternal diagnostics alongside a planned genomic lab. Management expects 18%-20% revenue growth in FY26, focusing on Eastern India dominance and cautious B2B and PPP expansion.